Latigo Biotherapeutics
- Market cap
- 1.00B
- P/E (TTM)i
- -9.04
- P/Bi
- -3.64
- EPSi
- -1.82
- Div yieldi
- 0.00%
- 52W posi
- 0%
Anonymous reader poll. Unscientific, not investment advice.
Valuation each multiple against its own 5-year range
Vs. peers Biotechnology
| Company | Market cap | P/E (TTM)i | P/Bi | Div yieldi |
|---|---|---|---|---|
| Latigo Biotherapeutics (LTGO) | 1.00B | -9.04 | -3.64 | 0.00% |
| Vertex Pharmaceuticals (VRTX) | 128.41B | 29.51 | 6.34 | 0.00% |
| Moderna (MRNA) | 78.42B | -24.61 | 11.60 | 0.00% |
| Regeneron Pharmaceuticals (REGN) | 75.37B | 18.12 | 2.38 | 0.50% |
| argenx SE (ARGX) | 51.17B | 31.00 | 6.08 | 0.00% |
| Revolution Medicines (RVMD) | 40.35B | -21.22 | 15.48 | 0.00% |
Other StockVane-tracked companies in the same industry.
Morningstar
Trading 25.3% below Morningstar's fair value estimate.
Fair value
Latigo Biotherapeutics Inc is assigned a 3-star quantitative star rating, reflecting our opinion that this share class is a balanced choice, but prudent investors should consider looking elsewhere. The stock currently trades at a 18% discount to our quantitative fair value estimate of $18.99 per share; however, caution is warranted due to this estimate's very high uncertainty rating.
We need more explanatory data to elaborate on this stock's star rating. We strive to explain the factors driving every rating we assign; however, this is not yet possible for a small fraction of our coverage universe.
Economic moat
The company's quantitative economic moat rating of none suggests any excess returns could erode quickly as competition arrives.
By Quantitative Equity Report
Quote time 2026-10-08 09:54:57 · For reference only, not investment advice and not tailored to your situation.